Increased serum apolipoprotein(a) in patients with chronic renal failure treated with continuous ambulatory peritoneal dialysis.
Patients with end-stage renal failure (ESRF) on renal replacement therapy are at significantly increased risk of cardiovascular disease. To determine whether altered concentrations of apolipoprotein(a) (apo(a)), the plasminogen-like protein moiety of the atherogenic particle lipoprotein(a), contributed to this increased risk, apo(a) concentrations were measured in 48 non-diabetic patients with ESRF treated by continuous ambulatory peritoneal dialysis (CAPD) therapy and compared with 65 controls. Apo(a) concentration was increased in CAPD patients compared to controls (geometric mean 419 units/l versus 137 units/l; ratio of means 3.06 (95% CI 1.95-4.80). We conclude that CAPD patients have increased apo(a) concentrations which may contribute to their increased risk of cardiovascular disease.
Murphy
B G
BG
Regional Nephrology Unit, Belfast City Hospital, Northern Ireland.
McNamee
P
P
Duly
E
E
Henry
W
W
Archbold
P
P
Trinick
T
T
D000328:Adult; D001053:Apolipoproteins / Q000097:blood*; D053241:Apoprotein(a); D002784:Cholesterol / Q000097:blood; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000628:therapy; D017270:Lipoprotein(a); D008297:Male; D010531:Peritoneal Dialysis, Continuous Ambulatory; D014280:Triglycerides / Q000097:blood
D001053:Apolipoproteins; D017270:Lipoprotein(a); D014280:Triglycerides; D002784:Cholesterol; D053241:Apoprotein(a)